Ireland-based Perrigo Company plc (NYSE, TASE: PRGO) announced yesterday that it has named James Dillard as its new executive vice president and chief scientific officer.
In this new role, Dillard will be responsible for providing global oversight and coordination to Perrigo's Research & Development, Quality, Regulatory and Innovation efforts. He will report to president and chief executive officer, Murray S Kessler.
Dillard is joining Perrigo from Altria Group Inc, where he served as senior vice president, Research, Development and Sciences and chief innovation officer. He also led the manufacturing, science and technology functions for United States Smokeless Tobacco Company, part of the Altria organisation. Between 1987 and 2001, he worked for the FDA, where he last served as director of the Division of Cardiovascular and Respiratory Devices. During his 14 years at the FDA, he held various leadership roles in the Center for Devices and Radiological Health and the Office of Device Evaluation.
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system